Carranza LS, Orozco OME, Olivares SA, Chán VR, Cárdenas LM

Language: Spanish
References: 9
Page: 465-468
PDF size: 193.99 Kb.

ABSTRACT

Background: Several studies have tried to evaluate in which estradiol (E₂) and testosterone (T) levels the climacteric symptoms appear, but this has not been possible at all.
Objective: To evaluate in which E₂ and T levels climacteric symptoms appear, as well as its relation with T/E2 ratio.
Material and methods: Twenty nine healthy climacteric women [perimenopausal (n = 13) or postmenopausal (n = 16)] which have not received nor were receiving hormone therapy were studied. Age, body mass index, waist hip ratio and menstrual status were documented. An analog visual scale was used to evaluate the intensity of 13 climacteric symptoms. A blood sample was taken for the measurement of E₂ and T measurement by radioimmunoassay. Pearson’s correlation analysis was done between the sum of scores of all climacteric symptoms and with the score obtained from each of the climacteric symptoms and E₂, T levels and T/ E₂ ratio. All patients gave their consent to participate in the study.
Results: The average age of women was 49.9 ± 5.1 years and the time since menopause 43.9 ± 53.2 months. The sum of the magnitudes of the symptoms was 71.2 ± 24.9. The average level of E₂ and T was 65.5 ± 101.1 pg/ml and 14.5 ± 10.7 ng/ml respectively. No correlation was observed between the sum of the magnitudes of the symptoms neither with the magnitude of each symptom with E₂ and T levels and T/E₂ ratio.
Conclusions: It was not possible to determine with precision in which E₂ and T levels climacteric symptoms appear and T/ E₂ ratio also was not useful for this purpose.

REFERENCES

1. Carranza LS. Atención integral del climaterio. 2ª ed. México: Masson Doyma, 2003.

2. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000;96:351-8.

3. Carranza LS, Barraza-Solorzano MC, Fernandez RL. Changes in vaginal cytology after various types of hormone replacement therapy, according to body mass index and body fat distribution in postmenopausal women. Int J Gynecol Obstet 2002;78:165-9.

4. Carranza LS. Actualidades en terapia hormonal durante el climaterio. México: Universum, 2008.

5. Carranza LS, Velasco Diaz G, Olivares A, Chan-Verdugo R, Herrera J. Correlation of Kupperman´s index with estrogen and androgen levels, according to weight and body fat distribution in postmenopausal women from Mexico City. Int J Fertil Womens Med 2006;51:83-8.

6. Carranza LS, Reyes Razo BP, Chan-Verdugo R. SUMEVA, a new way for climateric symptom evaluation and its correlation with FSH and estradiol levels. Int J Fertil Womens Med 2006;51:140-4.

7. Abe T, Furuhashi N, Yamaya Y, et al. Correlation between climacteric symptoms and serum levels of estradiol, progesterone, follicle stimulating hormone, and luteinizing hormone. Am J Obstet Gynecol 1977;129:65-7.

8. Aksel S, Schomberg DW, Tyrey L, Hammond CB. Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause. Am J Obstet Gynecol 1976;126:165-9.

9. Murillo A, Carranza-Lira S, Martínez-Trejo N, Santos González J. Variables epidemiológicas en la mujer posmenopáusica. Ginecol Obstet Mex 1999;67:478-83.